Indication
Complicated Urinary Tract Infection Including Acute Pyelonephritis
1 clinical trial
2 products
Clinical trial
A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
Meropenem